Morgan Stanley analyst Terence Flynn raised the firm’s price target on Bristol Myers (BMY) to $40 from $37 and keeps an Underweight rating on the shares. 2026 revenue and EPS guidance came in above consensus, but was driven by a higher than expected Eliquis guide, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Trump Trade: Argentina says U.S. to cut hundreds of tariffs
- Bristol Myers price target raised to $68 from $64 at BofA
- Bristol Myers price target raised to $72 from $62 at Guggenheim
- Bristol Myers price target raised to $64 from $60 at Citi
- Bristol Myers price target raised to $60 from $55 at Wells Fargo